the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.
Company profile
Ticker
DNA, DNA-WT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Acorda Therapeutics • Exelixis ...
Former names
Soaring Eagle Acquisition Corp., Spinning Eagle Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Ginkgo Bioworks, Inc. • Ginkgo Bioworks Securities Corporation • Concentric by Ginkgo, LLC • Zymergen Inc. ...
DNA stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Ginkgo Bioworks Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
27 Oct 23
8-K
Other Events
3 Oct 23
EFFECT
Notice of effectiveness
30 Aug 23
424B3
Prospectus supplement
29 Aug 23
8-K
Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity
29 Aug 23
CORRESP
Correspondence with SEC
25 Aug 23
UPLOAD
Letter from SEC
25 Aug 23
S-3
Shelf registration
23 Aug 23
Transcripts
DNA
Earnings call transcript
2023 Q3
8 Nov 23
DNA
Earnings call transcript
2023 Q2
9 Aug 23
DNA
Earnings call transcript
2023 Q1
10 May 23
DNA
Earnings call transcript
2022 Q4
1 Mar 23
DNA
Earnings call transcript
2022 Q3
15 Nov 22
DNA
Earnings call transcript
2022 Q2
16 Aug 22
DNA
Earnings call transcript
2022 Q1
17 May 22
DNA
Earnings call transcript
2021 Q4
29 Mar 22
DNA
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
4
Barry Canton
8 Dec 23
4
Jason R Kelly
8 Dec 23
4
Reshma P. Shetty
8 Dec 23
144
Notice of proposed sale of securities
8 Dec 23
144
Notice of proposed sale of securities
7 Dec 23
144
Notice of proposed sale of securities
7 Dec 23
144
Notice of proposed sale of securities
7 Dec 23
4
Mark E. Dmytruk
6 Dec 23
144
Notice of proposed sale of securities
6 Dec 23
144
Notice of proposed sale of securities
6 Dec 23
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn |
| Cash burn (monthly) | 25.81 mm | 20.91 mm | 100.97 mm | 77.81 mm | 24.52 mm | 28.52 mm |
| Cash used (since last report) | 61.01 mm | 49.41 mm | 238.64 mm | 183.89 mm | 57.94 mm | 67.40 mm |
| Cash remaining | 1.03 bn | 1.05 bn | 855.98 mm | 910.73 mm | 1.04 bn | 1.03 bn |
| Runway (months of cash) | 40.0 | 50.0 | 8.5 | 11.7 | 42.3 | 36.0 |
Institutional ownership, Q3 2023
85.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 335 |
| Opened positions | 58 |
| Closed positions | 25 |
| Increased positions | 135 |
| Reduced positions | 55 |
| 13F shares | Current |
|---|---|
| Total value | 2.20 tn |
| Total shares | 1.37 bn |
| Total puts | 2.93 mm |
| Total calls | 2.48 mm |
| Total put/call ratio | 1.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Baillie Gifford & Co | 238.81 mm | $432.24 bn |
| ARK Investment Management | 182.19 mm | $329.77 bn |
| Cascade Investment, L.L.C. | 151.87 mm | $1.73 bn |
| Viking Global Investors | 143.09 mm | $258.98 bn |
| Vanguard | 132.32 mm | $239.49 bn |
| BLK Blackrock | 72.70 mm | $131.59 bn |
| Anchorage Capital Group, L.L.C. | 69.85 mm | $126.44 bn |
| CMTDF Sumitomo Mitsui Trust | 58.75 mm | $106.33 bn |
| Nikko Asset Management Americas | 58.75 mm | $106.33 bn |
| MS Morgan Stanley | 49.77 mm | $90.08 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Dec 23 | Reshma P. Shetty | Class A Common Stock | Sell | Dispose S | Yes | Yes | 1.315 | 37,650 | 49.51 k | 12,449,844 |
| 7 Dec 23 | Jason R Kelly | Class A Common Stock | Sell | Dispose S | No | Yes | 1.313 | 100,000 | 131.30 k | 4,494,680 |
| 7 Dec 23 | Barry Canton | Class A Common Stock | Sell | Dispose S | No | Yes | 1.315 | 37,650 | 49.51 k | 12,449,844 |
| 6 Dec 23 | Reshma P. Shetty | Class A Common Stock | Sell | Dispose S | No | Yes | 1.323 | 37,650 | 49.81 k | 12,449,854 |
| 6 Dec 23 | Jason R Kelly | Class A Common Stock | Sell | Dispose S | No | Yes | 1.323 | 100,000 | 132.30 k | 4,594,680 |
| 6 Dec 23 | Barry Canton | Class A Common Stock | Sell | Dispose S | Yes | Yes | 1.323 | 37,650 | 49.81 k | 12,449,854 |
| 4 Dec 23 | Mark E. Dmytruk | Class A Common Stock | Sell | Dispose S | No | No | 1.387 | 42,402 | 58.81 k | 676,844 |
| 1 Dec 23 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 1,634 | 0.00 | 719,246 |
| 1 Dec 23 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 18,125 | 0.00 | 717,612 |
| 1 Dec 23 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 65,281 | 0.00 | 699,487 |
News
Brazil's Agrivalle Inks New Partnership With Ginkgo Bioworks To Advance Next-Gen Ag Biological Products; No Terms Disclosed
8 Dec 23
Synplogen, Ginkgo Bioworks Announce Plans To Accelerate Global DNA Manufacturing And Gene Therapy Platform Services In Japan
6 Dec 23
Dutch ingredients Firm Vivici Partners With Ginkgo Bioworks For Alternative Protein Development
27 Nov 23
Vivici Picks Ginkgo Bioworks To Extend Their Range Of Novel Dairy Proteins
27 Nov 23
Vivici BV And Ginkgo Bioworks Collaborate On Next-Gen Functional Alternative Protein
27 Nov 23
Press releases
Alveolus Bio Enters Into Strategic Collaboration with BiomEdit
8 Dec 23
Agrivalle and Ginkgo Bioworks Enter Multiyear Strategic Partnership to Accelerate Next-Gen Ag Biological Products
8 Dec 23
Synplogen and Ginkgo Bioworks Announce Plans to Accelerate Global DNA Manufacturing and Gene Therapy Platform Services in Japan
6 Dec 23
Small Cap Companies Spearheading Innovation in the Biopharma Healthcare Sector" INBS, RDHL, CDIO, VTAK, DNA
30 Nov 23
Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins
27 Nov 23